• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,462.21 2,845.63
( 3.81%)
Global Indices
Nasdaq
46,614.19 -76.70
(-0.16%)
Dow Jones
6,639.23 6.40
(0.10%)
Hang Seng
56,345.93 2,916.37
(5.46%)
Nikkei 225
10,352.49 -83.80
(-0.80%)
Forex
USD-INR
92.93 0.25
(0.27%)
EUR-INR
107.23 0.49
(0.46%)
GBP-INR
122.94 0.71
(0.58%)
JPY-INR
0.58 0.00
(0.32%)

EQUITY - MARKET SCREENER

BSE 200
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
1003
N.A
0
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
21.88
31984281
EPS(TTM)
Face Value()
Div & Yield %
0
100
1.2
 

Pfizer gains after Q2 PAT rises 19% YoY
Nov 13,2025
On a standalone basis, net sales stood at Rs 642.34 crore, rising 9.1% year-on-year from Rs 588.59 crore in Q2 FY25 and 6.5% sequentially from Rs 603.05 crore in Q1 FY26.

Net profit (PAT) rose 19.4% YoY to Rs 189.02 crore, compared with Rs 158.35 crore in Q2 FY25, as current tax expense increased 9.4% to Rs 65.49 crore. Sequentially, PAT was down 1.4% from Rs 191.75 crore in Q1 FY26.

Profit before tax (PBT) climbed 18.7% YoY to Rs 255.37 crore, though slightly lower by 1.6% QoQ.

Total expenditure inched up 3.3% YoY and 4.9% QoQ to Rs 412.41 crore. Raw material costs declined 8.7% YoY to Rs 70 crore, while employee expenses fell 6% YoY to Rs 94.67 crore. Depreciation stood at Rs 14.28 crore, down 4.74% year-on-year, while interest expenses were steady at Rs 2.13 crore.

Net cash flow from operating activities stood at Rs 599.47 crore in H1 FY26, as against a cash flow of Rs 349.43 crore in H1 FY25.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.